Hepatic and extrahepatic malignancies and primary sclerosing cholangitis

Schrumpf, E.; Boberg, K.M.
February 2003
Gut;Feb2003, Vol. 52 Issue 2, p165
Academic Journal
Background: Although primary sclerosing cholangitis (PSC) has long been described as a strong risk factor for the development of cholangiocarcinoma, there are few good epidemiological studies which have examined its frequency. In addition, the risk of developing other malignancies is unknown. Excellent health information systems in Scandinavia provide the opportunity to examine such associations in rare diseases. Objective: To assess the risk of hepatobiliary and extrahepatic malignancy in a large Swedish cohort of patients with PSC. Design: Follow up of a large case series of patients with PSC comparing the frequency of malignancy with that in the general Swedish population. Patients: A total of 609 patients with a clinical, biochemical, and cholangiographic diagnosis of PSC, identified by hepatologists from all Swedish university hospitals. Follow up was from the National Swedish Cancer Registry; clinical follow up and median follow up time was 5.7 years. Results: Twenty eight per cent of cases died during follow up, 44% of malignancy. Cholangiocarcinoma occurred in 13% of the cohort, with an incidence of hepatobiliary carcinoma of 1.5% per year after the first year post diagnosis of PSC. The risk of pancreatic cancer was increased 14-fold compared with the general Swedish population. Conclusion: The major cause of death in PSC patients (excluding those undergoing liver transplantation) was cancer. Not only was the increased risk of hepatobiliary cancer confirmed, but a new discovery of an increased risk of pancreatic cancer in patients with PSC was described.


Related Articles

  • Isolation of a Novel Human Gene, MARKL1, Homologous to MARK3 and Its Involvement in Hepatocellular Carcinogenesis. Kato, Tatsushi; Satoh, Seiji; Okabe, Hiroshi; Kitahara, Osamu; Ono, Kenji; Kihara, Chikashi; Tanaka, Toshihiro; Tsunoda, Tatsuhiko; Yamaoka, Yoshio; Nakamura, Yusuke; Furukawa, Yoichi // Neoplasia;Jan2001, Vol. 3 Issue 1, p4 

    Activation of the Wnt-signaling pathway is known to play a crucial role in carcinogenesis of various human organs including the colon, liver, prostate, and endometrium. To investigate the mechanisms underlying hepatocellular carcinogenesis, we attempted to identify genes regulated by...

  • Interaction of cimetidine with P450 in a mouse model of hepatocarcinogenesis initiation. Caballero, F.; Gerez, E.; Batlle, A.; Vazquez, E. // British Journal of Cancer;2/12/2002, Vol. 86 Issue 4, p630 

    Many drugs and xenobiotics are lipophilic and they should be transformed into more polar water soluble compounds to be excreted. Cimetidine inhibits cytochrome P450. The aim of this study was to investigate the preventive and/or reversal action of cimetidine on cytochrome P450 induction and...

  • Significance of Hepatic Preneoplasia in Risk Identification and Early Detection of Neoplasia. Bannasch, Peter; Haertel, Thomas; Su, Qin // Toxicologic Pathology;Jan/Feb2003, Vol. 31 Issue 1, p134 

    Among the different types of liver tumor, hepatocellular neoplasms predominate by far in both animals and man. Consequently, preneoplastic foci of altered hepatocytes (FAH), preceding both hepatocellular adenomas and carcinomas, represent the most prevalent form of hepatic preneoplasia observed...

  • Molecular pathogenesis of human hepatocellular carcinoma. Thorgeirsson, Snorri S.; Grisham, Joe W. // Nature Genetics;Aug2002, Vol. 31 Issue 4, p339 

    Hepatocarcinogenesis is a slow process during which genomic changes progressively alter the hepatocellular phenotype to produce cellular intermediates that evolve into hepatocellular carcinoma. During the long preneoplastic stage, in which the liver is often the site of chronic hepatitis,...

  • Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of β-catenin and synergistic effect of p53 null alleles. Renard, Claire-Angélique; Fourel, Geneviève; Bralet, Marie-Pierre; Degott, Claude; De La Coste, Alix; Perret, Christine; Tiollais, Pierre; Buendia, Marie Annick // Oncogene;5/25/2000, Vol. 19 Issue 22, p2678 

    The intronless N-myc2 gene was originally identified as the major target of hepatitis virus insertion in woodchuck liver tumors. Here we report that transgenic mice carrying the N-myc2 gene controlled by woodchuck hepatitis virus (WHV) regulatory sequences are highly predisposed to liver cancer....

  • Editorial. Okita, Kiwamu // Journal of Gastroenterology;1998, Vol. 33 Issue 4, p604 

    Editorial. Comments on the detection of serum hepatitis B,C, and D viral nucleic acids and its implications in hepatocellular carcinoma. Role of hepatitis virus B in liver carcinogenesis; Discussion of hepatocarcinogenesis in humans.

  • Potential prognostic value of leptin receptor in hepatocellular carcinoma. S-N Wang // Journal of Clinical Pathology;Dec2006, Vol. 59 Issue 12, p1267 

    BACKGROUND: Obesity is associated with several human malignancies, including hepatocellular carcinoma (HCC). This association may result from the deregulated expression of adipokines. AIMS: To explore the potential role and the prognostic value of leptin receptor (Ob-R) in HCC. METHODS: 66...

  • Altered Hepatic Foci Revisited. Maronpot, R. R. // Toxicologic Pathology;Jan/Feb2003, Vol. 31 Issue 1, p53 

    Editorial. Comments on papers presented to the Workshop on Hepatic Preneoplasia: Quantitative Evaluation in Carcinogenesis Bioassays and Relevance for Human Hepatocarcinogenesis held in Heidelberg, Germany on June 29, 2002. Consequence of the scientific community's commitment to identifying...

  • OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Zhao, Xiangxuan; Tian, Changhai; Puszyk, William M; Ogunwobi, Olorunseun O; Cao, Mengde; Wang, Ton; Cabrera, Roniel; Nelson, David R; Liu, Chen // Laboratory Investigation (00236837);Jan2013, Vol. 93 Issue 1, p8 

    Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood. In this study, we show that sorafenib triggers cell growth inhibition and apoptosis in...


Read the Article


Sign out of this library

Other Topics